WEZENLA 45 mg, solution for injection bottle, 0.5 ml
Active ingredients: USTÉKINUMAB
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- WEZENLA 45 mg, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon en verre de 0,5 mL
- Marketing authorisation holder
- AMGEN TECHNOLOGY (IRELAND)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 30 Sept 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68430695CIP73029548CIP133400930295489Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| USTÉKINUMABsolution | 45 mg · un flacon de 0,5 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.